Inhibitex Announces Appointment of New Scientific Advisory Board: Recognized Thought Leaders to Advise Company on Promising Antiviral Pipeline

Inhibitex Announces Appointment of New Scientific Advisory Board: Recognized Thought Leaders to Advise Company on Promising Antiviral Pipeline

Business Wire - November 29, 2007

ATLANTA -- Inhibitex, Inc. (Nasdaq: INHX) today announced it has established a new scientific advisory board to provide the Company with scientific and clinical guidance on its ongoing research and development activities. The Company's scientific advisory board is composed of distinguished scientists and thought leaders with recognized expertise in virology and infectious diseases. Chairing the Company's scientific advisory board will be Erik De Clercq, MD, PhD, Professor Emeritus (active retired) at the Katholieke Universiteit Leuven, Belgium and President of the Rega Foundation (Rega Institut V.Z.W.). Dr. De Clercq has invented or co-invented a number of approved antivirals including tenofovir, one of the most widely-used drugs for the treatment of HIV AIDS.

Other members of the Company's scientific advisory board include:

* Joseph J. Eron, Jr., MD, Professor of Medicine, Division of Infectious Diseases, and Principal Investigator of the UNC AIDS Clinical Research Group, University of North Carolina, Chapel Hill, School of Medicine

* Charles Flexner, MD, Professor of Medicine, Pharmacology, Molecular Sciences (School of Medicine), and International Health (Bloomberg School of Public Health), Johns Hopkins University

* Vasu Nair, PhD, DSc, Head of the Department of Pharmaceutical and Biomedical Sciences, Director, Center for Drug Discovery, University of Georgia, and Georgia Research Alliance Eminent Scholar

* Robert T. Schooley, MD, Head of the Division of Infectious Disease, University of California, San Diego, former Chair of the NIAID's AIDS Clinical Trials Group, and member of the Department of Health and Human Services AIDS Drug Development Task Force

* Richard Whitley, MD, Professor of Pediatrics, Microbiology, Medicine and Neurosurgery, and Director of the Division of Pediatric Infectious Diseases, University of Alabama, Birmingham, and Director of the NIAID Collaborative Antiviral Study Group

"We are privileged to have this accomplished group of scientific and clinical thought leaders join our scientific advisory board," stated Russell H. Plumb, president and chief executive officer of Inhibitex. "During the past year, we have made significant progress in our strategy to build and develop a pipeline of differentiated, antiviral programs in important therapeutic areas including shingles, HIV and hepatitis C. The collective knowledge, expertise and insights that these individuals provide will be invaluable as we advance these antiviral programs through the development process."

About Inhibitex

Inhibitex, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company focused on the development of products that can treat, prevent or diagnose serious infections. In addition to its antiviral pipeline that includes FV-100 to treat shingles (herpes zoster), HIV integrase inhibitors, HCV polymerase inhibitors and nucleoside analogues with antiviral activity against cytomegalovirus (CMV), the Company has several programs and collaborations based upon its proprietary MSCRAMM(R) protein platform. These include Aurexis(R), a humanized monoclonal antibody being developed for the treatment, in combination with antibiotics, of serious Staphylococcus aureus bloodstream infections, including those caused by MRSA, as well as license agreements with Wyeth for the development of staphylococcal vaccines and 3M for the development of diagnostic products.

For additional information about Inhibitex, please visit www.inhibitex.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts included in this press release, including statements regarding the Company's plans to advance its antiviral programs, are forward-looking statements. These plans, intentions, expectations, or time estimates may not actually be achieved and various important factors could cause actual results or events to differ materially from the forward-looking statements that the Company makes, including risks that the results of future preclinical and clinical studies may not confirm prior findings and support the further development of the Company's programs, the Company being able to enroll patients in its clinical trials in a timely manner and other cautionary statements contained elsewhere herein and in its Annual Report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission, or SEC, on March 16, 2007, and its Quarterly Reports on Form 10-Q for March 31, June 30 and September 30, 2007 as filed with the SEC on May 10, August 9, and November 9, 2007, respectively. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which apply only as of the date of this press release.

There may be events in the future that the Company is unable to predict accurately, or over which it has no control. The Company's business, financial condition, results of operations and prospects may change. The Company may not update these forward-looking statements, even though its situation may change in the future, unless it has obligations under the Federal securities laws to update and disclose material developments related to previously disclosed information. The Company qualifies all of the information contained in this press release, and particularly its forward-looking statements, by these cautionary statements.

Inhibitex(R), MSCRAMM(R), and Aurexis(R) are registered trademarks of Inhibitex, Inc.

Contacts:

Inhibitex, Inc.

Russell H. Plumb, 678-746-1136

Chief Executive Officer

rplumb@inhibitex.com

Stern Investor Relations, Inc.

Laura Perry, 212-362-1200

laura@sternir.com
071129
BW071130

Copyright © 2007 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.

Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .